SciSparc Ltd. - Ordinary Shares (NQ:SPRC)

Clearmind Medicine Submits Three Additional International Patent Applications for Innovative MDMA, Ibogaine and Ketamine Compounds

February 27, 2024

From Clearmind Medicine Inc.

EXCLUSIVE: Psychedelic-Focused Firm Clearmind Medicine Submits Three New International Patent Applications For MDMA, Ibogaine And Ketamine Compounds ↗

February 27, 2024

Patent applications by Clearmind Medicine for novel compositions in collaboration with SciSparc. Clearmind's CEO, highlights the significant expansion of IP protection.

Via Benzinga

Topics Intellectual Property

Why Is SciSparc (SPRC) Stock Up 50% Today? ↗

January 24, 2024

News of an investment fund inking an equity purchase agreement with SciSparc is boosting underlying credibility and lifting SPRC stock.

With SciSparc announcing positive results stemming from its joint venture, the drug discovery implications are boosting SPRC stock.

Why Is SciSparc (SPRC) Stock Up 25% Today? ↗

December 13, 2023

SciSparc Ltd. (NASDAQ: SPRC) shares are trading higher Wednesday.

What's Going On With SciSparc Ltd Stock? ↗

December 13, 2023

Via Benzinga

Next-Gen Psychedelics Companies SciSparc And Clearmind Collaboration File 3 Patents ↗

February 21, 2024

SciSparc & Clearmind file patents for LSD, psilocybin, DMT blends, advancing psychedelic therapeutics for mental health.

Via Benzinga

Topics Intellectual Property

What's Going On With Psychedelic Drug-Developers SciSparc And Clearmind Stock? ↗

February 20, 2024

SciSparc Ltd. and Clearmind Medicine Inc. shares are trading higher Tuesday after the companies announced the submission of three international patent applications as part of the ongoing collaboration...

Via Benzinga

Topics Intellectual Property

Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗

February 20, 2024

Shares of Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results.

Via Benzinga

Clearmind Medicine Submits Three International Patent Applications for Next Generation Classic Psychedelic-Based Compounds

February 20, 2024

From Clearmind Medicine Inc.

SciSparc and Clearmind Continue to Strengthen International Patent Portfolio with Next Generation Classic Psychedelic-Based Compounds

February 20, 2024

SciSparc Announces Initiation of Patient Recruitment for its Clinical Trial with SCI-210 in Children with Autism Spectrum Disorder

January 29, 2024

Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More ↗

January 26, 2024

Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available.

Via Benzinga

Why BlackBerry Shares Are Trading Lower By Over 17%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

January 24, 2024

Shares of BlackBerry Limited (NYSE: BB) fell sharply during Wednesday’s session after the company announced a proposed private offering of $160 million of convertible senior notes. BlackBerry shares...

Via Benzinga

Crude Oil Rises Over 1%; DuPont Shares Plunge ↗

January 24, 2024

U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining around 150 points on Wednesday. The Dow traded up 0.36% to 38,040.66 while the NASDAQ rose 0.97% to 15,574.97. The...

Via Benzinga

Topics Stocks

Why SciSparc Stock Is Lighting Up ↗

January 24, 2024

SciSparc Ltd. shares are trading higher Wednesday after the company announced that it has entered into a standby equity purchase agreement with YA II PN, Ltd., a fund managed by Yorkville Advisors...

Via Benzinga

Dow Jumps 100 Points; Netflix Reports Strong Q4 Sales ↗

January 24, 2024

U.S. stocks traded higher this morning, with the Dow Jones index gaining more than 100 points on Wednesday. Following the market opening Wednesday, the Dow traded up 0.29% to 38,013.76 while the NASDAQ...

Via Benzinga

Topics Stocks

SciSparc Ltd. Announces $20 Million Standby Equity Purchase Agreement

January 24, 2024

SciSparc Advances the Acquisition Process of a Leading Vehicle Importer Company in Israel with the provision of a Bridge Loan of $1.4 million

January 19, 2024

The jump in Clearmind sent its market cap to $6 million. The study of psychedelic compounds to treat mental illness is growing.

Why Is Clearmind (CMND) Stock Up 40% Today? ↗

January 10, 2024

SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic-Based Treatments

January 04, 2024

Clearmind Medicine and SciSparc Reflect on Successful Collaboration in 2023 Aiming to Upgrade Wide Range of Psychedelic- Based Treatments

January 04, 2024

From Clearmind Medicine Inc.

Why Despegar.com Shares Are Trading Higher By Over 16%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

December 13, 2023

Shares of Despegar.com, Corp. (NYSE: DESP) rose sharply during Wednesday’s session after the company raised its FY23 financial guidance. The company said it now sees revenue of $690 million to $700...

Via Benzinga

SciSparc Announces Positive Results for MitoCareX Bio with its Drug Discovery Platform

December 13, 2023

SciSparc Provides Updates Regarding the Non-Binding Letter of Intent to Acquire Leading Vehicle Importer Company in Israel

December 07, 2023

Psychedelic-medicine specialist Clearmind Medicine posted encouraging study results, leading to a significant boost in CMND stock.

Why Is Clearmind Medicine (CMND) Stock Up 50% Today? ↗

December 05, 2023

Psyched: Defense Dept.'s Ketamine Trial, Cybin's Psilocybin, Metabolic Disorders, Reform Update And More ↗

December 05, 2023

Defense Dept. Funds Ketamine Study For PTSD Treatment

Via Benzinga

Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial

December 01, 2023

SciSparc Adopts Limited Duration Shareholder Rights Plan

November 28, 2023

SciSparc Announces Positive Results from its Weight Loss and Metabolic Disorder Program with its Proprietary Psychedelic-Based Treatment

November 28, 2023